Despite the introduction of novel pharmacologic medications like beta-blockers and angiotensin-converting-enzyme inhibitors (ACEIs) in HF management, the quality of life for these patients remains poor with the majority of them occurring as early as within 6-month [45, 46]. This evidence concerns the gene ACE and hydrops fetalis.